BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38607280)

  • 1. Prognostic Value of Preoperative MRI-derived 3D Quantitative Tumor Arterial Burden in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.
    Peng G; Huang XY; Wang YN; Cao XJ; Zhou X
    Radiol Imaging Cancer; 2024 May; 6(3):e230167. PubMed ID: 38607280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
    Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
    Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging.
    Byun J; Kim SY; Kim JH; Kim MJ; Yoo C; Shim JH; Lee SS
    Acta Radiol; 2021 Dec; 62(12):1548-1558. PubMed ID: 33197329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization.
    Lee BC; Jeong YY; Heo SH; Kim HO; Park C; Shin SS; Cho SB; Koh YS
    Acad Radiol; 2022 Sep; 29(9):e178-e188. PubMed ID: 35151549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
    Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
    Niu XK; He XF
    World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma.
    Auer TA; Müller L; Schulze D; Anhamm M; Bettinger D; Steinle V; Haubold J; Zopfs D; Pinto Dos Santos D; Eisenblätter M; Gebauer B; Kloeckner R; Collettini F
    Radiology; 2024 Feb; 310(2):e232044. PubMed ID: 38319166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Rohan T; Uher M; Matkulčík P; Zavadil J; Ostřížková L; Kiss I; Andrašina T; Válek V
    Klin Onkol; 2020; 33(3):214-219. PubMed ID: 32683878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
    Borde T; Nezami N; Laage Gaupp F; Savic LJ; Taddei T; Jaffe A; Strazzabosco M; Lin M; Duran R; Georgiades C; Hong K; Chapiro J
    Radiology; 2022 Jul; 304(1):228-237. PubMed ID: 35412368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome.
    Liu D; Liu M; Su L; Wang Y; Zhang X; Long H; Kuang M; Xie X; Lin M
    J Vasc Interv Radiol; 2019 Dec; 30(12):1879-1886. PubMed ID: 31669087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
    Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
    Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Ho SY; Liu PH; Hsu CY; Ko CC; Huang YH; Su CW; Lee RC; Tsai PH; Hou MC; Huo TI
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3196-3203. PubMed ID: 34159651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
    AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.